label for rilpivirine tablets was revised to reflect the oral lead-in recommendations for use with cabotegravir. Chemistry Like etravirine, a second-generation NNRTI approved in 2008, rilpivirine is a diarylpyrimidine (DAPY). The tablets contain rilpivirine hydrochloride, while the injection contains free rilpivirine. History Rilpivirine entered phase III clinical trials in April 2008, and was approved for use in the United States in May 2011 under the brand name Edurant. On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for rilpivirine under the trade name Rekambys, intended for the treatment of human immunodeficiency virus type-1 (HIV-1) infection in combination with cabotegravir injection. It was approved for medical use in the European Union in December 2020. The two medicines are the first antiretrovirals that come in a long-acting injectable formulation. References External links GSK plc brands Non-nucleoside reverse transcriptase inhibitors Nitriles Pyrimidines Johnson & Johnson brands